• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·000590.SZ
Share

Guhan Pharmaceutical Group Co., Ltd. Stocks

CN¥ 8.21Last Updated 14.07.2026

Issuer Rating

3/7
Performance

Poor

Risk

Limited

Recommendation

Sell

Market Cap

CN¥ 289.44M

CN¥ 8.21
Key Takeaways

Risk factor

Meaningful price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Guhan Pharmaceutical Group Co., Ltd., along with its various subsidiaries, operates as a prominent Chinese pharmaceutical enterprise. The company focuses on the production and distribution of traditional Chinese medicine (TCM), conventional chemical pharmaceuticals, and health supplements within the domestic market. Its business activities are organized into specific segments, including the manufacturing and sale of traditional Chinese medicine, the manufacturing and sale of Western medicine, and a range of other operations. The company boasts a comprehensive product catalog featuring both prescription and over-the-counter (OTC) drugs. This selection includes tonics and health-boosting preparations, medications for cardiovascular and cerebrovascular conditions, nutritional products for children, cold and flu remedies, and detoxifying agents. Beyond its core manufacturing, Guhan Pharmaceutical is involved in a diverse array of additional services and ventures. These encompass health and nutrition advisory services, the cultivation of Chinese medicinal herbs, extensive medical research and experimental development, planning for cultural and artistic exchanges, general medical consultations, online sales, technology promotion, consulting agent services, outpatient care, and comprehensive pharmaceutical wholesale and retail operations. Founded in 1956, the company is headquartered in Hengyang, China. It was previously known as Tus-Pharmaceutical Group Co., Ltd., officially adopting its current name, Guhan Pharmaceutical Group Co., Ltd., in November 2025.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is overpriced on P/FCF.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

15.07.2026 03:24

Lucid's stock plummeted following news of a possible bankruptcy. At one point, it was down 57%.

15.07.2026 02:16

"The Prisoner's Dilemma": JPMorgan Warns of a Threat to Coinbase and Circle's Profits

15.07.2026 01:24

Inflation data pushed the indices higher. Software developers are under pressure again

15.07.2026 00:57

Biogen shares fell after disappointing data on its Alzheimer's drug

14.07.2026 23:31

Software developers' stocks plummeted following IBM's warning. What's wrong with the sector?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026